(K Saltiki and O Karapanou contributed equally to this work)
A cohort of radioiodine-refractory differentiated thyroid cancer patients (RAI-R DTC) in a tertiary center underwent therapeutic interventions according to disease progression rate and metastasis location. We evaluated the independent impact of local and/or systemic treatments on final outcomes in 122 RAI-R DTC patients (44.3% men, age at diagnosis 51.98 ± 15.8 years) who were followed up for 9.5 years (1.4–50). Patients were divided into two groups: those with only locoregional persistent disease: group 1, n = 27 (22.1%) and those with distant metastases: group 2, n = 95 (77.9%). Patients from group 1 underwent mainly local procedures. The final outcome was 4/27 (14.8%) partial-response (PR) and 23/27 (85.2%) stable disease (SD). Of group 2 patients, 10/95 underwent active surveillance for micrometastatic disease, and the remaining received either only local treatments (40/95) or TKIs ± local treatments (45/95). The final outcome was PR in 7/95 (7.4%), SD in 38 (40%) and progressive disease in 50 (52.6%). Concerning group 2 in Kaplan–Meier analysis, local metastasis stabilization with local and/or systemic therapy had a favorable effect on survival (P < 0.02). Those treated with TKIs + local procedures, despite having more aggressive tumors, achieved more frequently local stabilization and had a similar outcome compared to those treated with only TKIs (P = 0.007). For group 2, in Cox proportional hazard analysis during the follow-up period, younger age at diagnosis and maintenance of tumor differentiation are predictors of more favorable OS and cancer-specific survival. In conclusion, the implementation of local procedures in RAI-R DTC management stabilizes metastatic lesions and potentially enhances survival. Further studies are warranted to validate these findings.
Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
| Sept 2018 onwards | Past Year | Past 30 Days | |
|---|---|---|---|
| Full Text Views | 15 | 15 | 15 |
| PDF Downloads | 21 | 21 | 21 |
Online ISSN: 1479-6821
Print ISSN: 1351-0088
Strengthening biomedical communities
to advance science and health
CONTACT US
Bioscientifica Ltd | Starling House | 1600 Bristol Parkway North | Bristol BS34 8YU | UK
Bioscientifica Ltd | Registered in England no 3190519
